Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IMMX Immix Biopharma
2.794-0.076-2.65%
Close
02/08 16:00 ET
2.770-0.024-0.84%
Post Mkt Price 02/08 19:31 ET
High
2.930
Open
2.810
Turnover
305.52K
Low
2.700
Pre Close
2.870
Volume
109.14K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersSenesTech (NASDAQ:SNES) shares moved upwards by 11.1% to $4.11 during Tuesday's after-market session. SenesTech's trading volume hit 206.4K shares by close, accounting for 177.0% of its average
Immix Biopharma Announces Dosing of First 2 Patients in Its IMX-110 + BeiGene/Novartis Anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients With Advanced Cancer
IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically "cold" tumors "hot"Initial data anticipated in 1H 2023LOS ANGELES,
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In January: Where Do SPY, Tesla, Apple And Ford Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
In January 2023, the 17th new patient was dosed with IMX-110 to datePositive safety data enabled continued dosing of previously enrolled patients Patients undergo CT scans every 8 weeks after dosing t
DexCom, Lululemon Athletica, Arrowhead Pharmaceuticals Among Premarket Losers' Pack
Immix Unit Says AL Amyloidosis Drug Candidate Showed 100% Complete Response Rate in Clinical Study
10:55 AM EST, 01/06/2023 (MT Newswires) -- Immix Biopharma (IMMX) subsidiary Nexcella said Friday treatment with NXC-201 showed a 100% complete response rate in relapsed/refractory AL amyloidosis pati
Immix Biopharma's Nexcella Announces Additional Clinical Data on NXC-201
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersSpruce Biosciences (NASDAQ:SPRB) stock rose 80.0% to $2.25 during Friday's pre-market session. The market value of their outstanding shares is at $53.0 million. CytomX Therapeutics (NASDAQ:CTMX
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients to-dateClinical data published December 2022 in Clinical Cancer Research demonstrated 100%
Hadasit And BIRAD Enter Research And License Agreement With Immix BioPharma
Company Overview
More
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
CEO： Dr. Ilya Rachman
Market： NASDAQ
Listing Date： 12/16/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet